More Changes In Carcinogenesis Program At NCI: Gori, Workshops Out, Branch Chiefs Running It
In Brief: NCI Can Proceed With Grant, Contract Awards At Full FY 1978 Level; Rundles Heads ACS
Board Defers core Guideline changes, Asks Subcommittee For Alternate Plans
First analysis From Profiles Reveal New Data On Centers
New research Suggested For Immunobiology
NCI Offers Chlorozotocin
To Industry for Development, NDA
Drug Development Gets Extra $500,000
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Break Through Cancer’s Tyler Jacks: “We’ve created a new operating model for collaborative cancer research.”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - As more people are surviving cancer, we must continue funding bold science









